Your session is about to expire
← Back to Search
Hormone Replacement Therapy
Hormone Replacement Therapy for Hypothyroidism
Phase 2
Waitlist Available
Research Sponsored by Sention Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new hormone replacement therapy called ST-1891 in patients with primary hypothyroidism. The goal is to help patients whose thyroid glands don't produce enough hormones. Levothyroxine has been the standard treatment for hypothyroidism since the 1950s.
Eligible Conditions
- Hypothyroidism
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: ST-1891Experimental Treatment1 Intervention
Group II: LevothyroxineActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ST-1891
2022
Completed Phase 2
~490
Find a Location
Who is running the clinical trial?
Sention Therapeutics, LLCLead Sponsor
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a medical condition or had surgery that might affect how your body processes ST-1891 or levothyroxine.You have been taking levothyroxine for your thyroid for at least a year before the screening.You are not taking any medications that are not allowed in the study.You have been diagnosed with primary hypothyroidism.
Research Study Groups:
This trial has the following groups:- Group 1: ST-1891
- Group 2: Levothyroxine
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Hypothyroidism Patient Testimony for trial: Trial Name: NCT05412979 — Phase 2
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger